FDA Expands Anktiva Approval to Papillary-Only Bladder Cancer That Resists BCG ...

The FDA expanded Anktiva's approval to include adults with high-grade, papillary-only non-muscle-invasive bladder cancer unresponsive to BCG, offering a nonsurgical treatment alternative to radical cystectomy. This decision was based on clinical trial data indicating durable responses and bladder preservation rates, although regular monitoring remains critical due to progression risks.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 14 Oct 2026 and 17 Oct 2026.